Revvity HTRF Human Total SALL4 Detection Kit, 50,000 Assay Points

SALL4 is a transcription factor from the spalt-like (SALL) gene family, known for its zinc finger domains and crucial role in maintaining the pluripotency and self-renewal of embryonic stem cells. Although SALL4 expression decreases significantly in most adult tissues, it is aberrantly reactivated in various cancers, promoting cell proliferation and stem cell-like characteristics in malignant cells. This re-expression links SALL4 to tumorigenesis and poor prognosis, making it a notable biomarker and potential therapeutic target in oncology.

Immunomodulatory imide drugs (IMIDs), including lenalidomide and thalidomide derivatives, have shown promise in targeting SALL4, especially the SALL4A isoform. These drugs have demonstrated anti-tumor activity but pose a significant risk due to their teratogenic effects, causing severe birth defects. Despite this limitation, SALL4 remains an attractive target in aggressive cancers where its expression is aberrant, especially when other treatments have failed. Ongoing research aims to develop more selective and less toxic inhibitors, balancing the therapeutic benefits of targeting SALL4 with the risks of teratogenicity, thus offering new potential in cancer treatment.